Cargando…

Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab

INTRODUCTION: Mucinous tubular and spindle cell carcinoma is a rare subtype of renal cell carcinoma. Little is known regarding the efficacy of systemic therapy on its metastatic form because of its rarity. CASE PRESENTATION: We present the case of a patient with metastatic mucinous tubular and spind...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuchizawa, Hirotaka, Kijima, Toshiki, Takada‐Owada, Atsuko, Nagashima, Yoji, Okazaki, Akihito, Yokoyama, Megumi, Nishihara, Daisaku, Ishida, Kazuyuki, Kamai, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413205/
https://www.ncbi.nlm.nih.gov/pubmed/34497997
http://dx.doi.org/10.1002/iju5.12342
_version_ 1783747612055175168
author Fuchizawa, Hirotaka
Kijima, Toshiki
Takada‐Owada, Atsuko
Nagashima, Yoji
Okazaki, Akihito
Yokoyama, Megumi
Nishihara, Daisaku
Ishida, Kazuyuki
Kamai, Takao
author_facet Fuchizawa, Hirotaka
Kijima, Toshiki
Takada‐Owada, Atsuko
Nagashima, Yoji
Okazaki, Akihito
Yokoyama, Megumi
Nishihara, Daisaku
Ishida, Kazuyuki
Kamai, Takao
author_sort Fuchizawa, Hirotaka
collection PubMed
description INTRODUCTION: Mucinous tubular and spindle cell carcinoma is a rare subtype of renal cell carcinoma. Little is known regarding the efficacy of systemic therapy on its metastatic form because of its rarity. CASE PRESENTATION: We present the case of a patient with metastatic mucinous tubular and spindle cell carcinoma who achieved durable complete remission of multiple osseous metastases after undergoing cytoreductive nephrectomy followed by combination immunotherapy (ipilimumab plus nivolumab). Immunohistochemical analyses of the primary tumor revealed the presence of the tumor‐infiltrating immune cells, including activated CD8(+) T cells and PD‐L1 expression, suggesting an immunologically hot tumor. CONCLUSION: Combination immunotherapy was a viable treatment option for this disease. Immunohistochemical analyses of the tumor‐infiltrating immune cells predicted the efficacy of immune checkpoint inhibitors against rare renal cancers.
format Online
Article
Text
id pubmed-8413205
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84132052021-09-07 Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab Fuchizawa, Hirotaka Kijima, Toshiki Takada‐Owada, Atsuko Nagashima, Yoji Okazaki, Akihito Yokoyama, Megumi Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao IJU Case Rep Case Reports INTRODUCTION: Mucinous tubular and spindle cell carcinoma is a rare subtype of renal cell carcinoma. Little is known regarding the efficacy of systemic therapy on its metastatic form because of its rarity. CASE PRESENTATION: We present the case of a patient with metastatic mucinous tubular and spindle cell carcinoma who achieved durable complete remission of multiple osseous metastases after undergoing cytoreductive nephrectomy followed by combination immunotherapy (ipilimumab plus nivolumab). Immunohistochemical analyses of the primary tumor revealed the presence of the tumor‐infiltrating immune cells, including activated CD8(+) T cells and PD‐L1 expression, suggesting an immunologically hot tumor. CONCLUSION: Combination immunotherapy was a viable treatment option for this disease. Immunohistochemical analyses of the tumor‐infiltrating immune cells predicted the efficacy of immune checkpoint inhibitors against rare renal cancers. John Wiley and Sons Inc. 2021-06-29 /pmc/articles/PMC8413205/ /pubmed/34497997 http://dx.doi.org/10.1002/iju5.12342 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Fuchizawa, Hirotaka
Kijima, Toshiki
Takada‐Owada, Atsuko
Nagashima, Yoji
Okazaki, Akihito
Yokoyama, Megumi
Nishihara, Daisaku
Ishida, Kazuyuki
Kamai, Takao
Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
title Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
title_full Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
title_fullStr Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
title_full_unstemmed Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
title_short Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
title_sort metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413205/
https://www.ncbi.nlm.nih.gov/pubmed/34497997
http://dx.doi.org/10.1002/iju5.12342
work_keys_str_mv AT fuchizawahirotaka metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab
AT kijimatoshiki metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab
AT takadaowadaatsuko metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab
AT nagashimayoji metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab
AT okazakiakihito metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab
AT yokoyamamegumi metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab
AT nishiharadaisaku metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab
AT ishidakazuyuki metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab
AT kamaitakao metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab